Polar Capital Holdings’s Summit Therapeutics SMMT Stock Holding History

Polar Capital Holdings’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-746,393	Closed	-$15.4M	–	293
2025 Q3	$15.4M	Sell	746,393 -253,607	-25%	-$6.15M	0.07%	172
2025 Q2	$21.3M	Buy	+1,000,000	New	+$22.8M	0.11%	139
2022 Q3	–	Sell	-5,599,407	Closed	-$5.6M	–	438
2022 Q2	$5.6M	Sell	5,599,407 -673,102	-11%	-$944K	0.03%	234
2022 Q1	$15.4M	Buy	6,272,509 +154,598	+3%	+$390K	0.07%	191
2021 Q4	$16.5M	Sell	6,117,911 -284,498	-4%	-$1.37M	0.06%	188
2021 Q3	$32.1M	Sell	6,402,409 -559,504	-8%	-$4.01M	0.13%	134
2021 Q2	$51.9M	Buy	6,961,913 +803,113	+13%	+$5.27M	0.23%	99
2021 Q1	$36.2M	Buy	6,158,800 +358,800	+6%	+$2.31M	0.22%	113
2020 Q4	$27.3M	Buy	+5,800,000	New	+$24.6M	0.17%	129

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

PCMH

Polymer Capital Management (HK) Hong Kong $1.98B AUM 210.13% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Polar Capital Holdings's SMMT Position: Q4 2025 in Review

Polar Capital Holdings sold out of Summit Therapeutics (SMMT) in Q4 2025, closing a stake of 746,393 shares — an estimated $15.4M sold.

Polar Capital Holdings first reported a position in SMMT in Q4 2020 and held it in 9 quarters. The position peaked at $51.9M in Q2 2021. 206 funds tracked by Wall St. Rank hold SMMT as of Q4 2025.

Polar Capital Holdings reported no remaining Summit Therapeutics position as of Q4 2025 after selling out during the quarter.
Polar Capital Holdings sold 746,393 Summit Therapeutics shares in Q4 2025, an estimated $15.4M.
Polar Capital Holdings first reported a position in Summit Therapeutics in Q4 2020 and held it in 9 quarters.
Polar Capital Holdings's Summit Therapeutics position peaked at $51.9M in Q2 2021.
206 funds tracked by Wall St. Rank held Summit Therapeutics as of Q4 2025.

Based on Polar Capital Holdings's 13F filing for Q4 2025, filed 17 Feb 2026.